<DOC>
	<DOCNO>NCT01911936</DOCNO>
	<brief_summary>This study evaluate safety tolerability estimate MTDand/or recommend dose .</brief_summary>
	<brief_title>A Phase I Study LJM716 Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This phase I , open-label , dose-escalation study establish MTD and/or RDE LJM716 single agent Japanese patient advance solid tumor . The study consist dose escalation part dose expansion part .</detailed_description>
	<criteria>1 . Patients follow indication : ) ( Dose escalation part ) : HER2 overexpressing locally advanced/ metastatic breast cancer gastric cancer effective treatment option exists : For breast cancer : document 3+ immunohistochemistry , amplification situ hybridization For gastric cancer ( include GE junction tumor ) : document 3+ immunohistochemistry , 2+ immunohistochemistry amplification situ hybridization OR , ii ) ( Dose escalation part ) : Recurrent metastatic SCCHN regardless HER2 status effective treatment option exist OR , iii ) Recurrent metastatic ESCC regardless HER2 status effective treatment option exist 2 . ECOG Performance Status 02 3 . Must recover adverse effect prior surgery , radiotherapy antineoplastic therapy . Alopecia CTCAE Grade 1 peripheral neuropathy acceptable . 4 . Willingness ability comply study procedures 5 . Written inform consent obtain prior screen procedure 6 . During dose expansion part study , patient must least one measurable lesion define RECIST v1.1 criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>CLJM716 ,</keyword>
	<keyword>Japanese patient ,</keyword>
	<keyword>Neoplasms</keyword>
</DOC>